October 30, 2025 || Response to the Draft Report of the Health Economics Methods Advisory (HEMA): “Defining Appropriate Benefits for Economic Evaluation of Health Care Technologies” || View
July 31, 2025 || Statement from the Center for Innovation & Value Research on President Trump’s July 31st Ultimatum on Most Favored Nation || View
June 26, 2025 || The Center Comments on the CMS Draft Guidance for the Medicare DPNP || View
May 13, 2025 || The Center Responds to MFN Executive Order || View
June 28, 2024 || The Center (formerly IVI) Provides Comments on CMS’ Drug Price Negotiation Program || View
September 28, 2023 || IVI Responds to Final ICER Value Assessment Framework || View
August 29, 2023 || IVI Responds to CMS’ Announcement of Prescription Drugs Under the Inflation Reduction Act || View
July 26, 2023 || Maximizing Value and Equity: CMS Must Prioritize Value, Equity, and Patient Engagement in Drug Price Negotiation Program Implementation || View
July 11, 2023 || IVI Submits Comments on FDA’s Patient-Focused Drug Development Program || View
June 30, 2023 || IVI Responds to the ICER 2023 Value Assessment Framework || View
May 5, 2023 || IVI Makes Patient-Centered Recommendations to CMS for Medicare DPNP || View
March 19, 2023 || IVI Statement in Response to ICER’s Health Equity Report || View
August 23, 2022 || IVI Statement on the Inflation Reduction Act Becoming Law || View
December 16, 2022 || Patient Perspectives: An Integral Part of Health Technology Assessment Methodology || View